Rezolute (RZLT) Stock Forecast & Price Target

Rezolute is expected to see a potential 175+% upside from its current levels, with a projected peak sales of ~$850M in the U.S alone if the upLIFT registrational study for tHI is successful. The recent interim update de-risks the upLIFT readout, and the company may see additional 50+% potential upside if a viable path forward emerges in cHI. However, there are some potential risks for regulatory delays or challenges in obtaining FDA approvals, as well as potential challenges in scaling operations to meet FDA guidelines. Overall, the positive interim data from the upLIFT trial and potential for future success in the tHI indication make Rezolute a top pick for potential growth and value creation with a high likelihood of positive returns for investors.

Rezolute is facing challenges with its upLIFT trial, with a potential ~99% chance of failure based on its current response rate across EAP and upLIFT. Furthermore, despite promising results, the sample size for clinical efficacy is too small to make a definitive conclusion, and previous studies have shown that only a small percentage of patients may respond. Additionally, the company's main drug candidate, ersedetug, is targeting a small patient population and may face difficulty in obtaining regulatory approval and generating substantial revenue.